Aldehyde bright stem cells can be identified in the subject's blood or bone marrow by staining with a substrate of aldehyde dehydrogenase, an enzyme that is highly expressed in stem cells. Stem cells can self-renew through cell division giving rise to more stem cells and, under certain conditions, can be induced to become cells with a special function in the body such as nerves and blood vessels. It is believed that in response to long-range signals, stem cells are able to migrate from the blood circulation into areas of injury or degeneration and participate in the repair response. Aldehyde bright stem cell populations of human bone marrow have been shown to be highly enriched in cell types thought to mediate tissue repair, including endothelial, mesenchymal, neural and hematopoietic progenitor cells.
"We are pleased to have an opportunity to highlight several of our ZFP Therapeutic programs at this meeting focused on development of novel cell therapies," said Edward Lanphier, Sangamo's president and CEO. "The stem cell data that Dr. Mitchell presented align well with observations that we and our collaborators have made in both preclinical animal models of angiogenesis and in our early clinical studies of our ZFP activator of VEGF, SB-509. We look forward to the data from our ongoing Phase 2 clinical trial, SB-509-703 which is designed to investigate this potentially useful effect of our ZFP Therapeutic as a means of mobilizing cells that have a function in tissue repair and regeneration."
Other Presentations of Data from Sangamo Programs at the ISCT Meeting
In addition, preclinical data is being presented from Sangamo's ZFP
Therapeutics programs in glioblastoma and HIV/AIDS.
-- Sunday, May 18: Oral Session: Immunotherapy and Dendritic Cells;
"Zinc Finger Nucleases Targeting the Glucocortic
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved